Clinical Trial Update: Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating safety of ALLO-ASC-DFU in subjects with Dystrophic Epidermolysis Bullosa has completed Phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• ALLO-ASC-DFU

Snippet

Sponsor: Anterogen Co., Ltd. | Conditions: Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: COMPLETED